Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs

To evaluate a radiomic strategy for predicting progression in advanced gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with somatostatin analogs (SSAs). Fifty-eight patients with GEP-NETs and liver metastases, with baseline computerized tomography (CT) scans from June 2013 to...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroendocrinology 2024-11, p.e13472
Main Authors: Polici, Michela, Caruso, Damiano, Masci, Benedetta, Marasco, Matteo, Valanzuolo, Daniela, Dell'Unto, Elisabetta, Zerunian, Marta, Campana, Davide, De Santis, Domenico, Lamberti, Giuseppe, Iannicelli, Elsa, Prosperi, Daniela, Annibale, Bruno, Laghi, Andrea, Panzuto, Francesco, Rinzivillo, Maria
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate a radiomic strategy for predicting progression in advanced gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with somatostatin analogs (SSAs). Fifty-eight patients with GEP-NETs and liver metastases, with baseline computerized tomography (CT) scans from June 2013 to November 2020, were studied retrospectively. Data collected included progression-free survival (PFS), overall survival (OS), tumor grading, death, and Ki67 index. Patients were categorized into progressive and non-progressive groups. Two radiologists performed 3D liver segmentation on baseline CT scans using 3DSlicer v4.10.2. One hundred six radiomic features were extracted and analyzed (T-test or Mann-Whitney). Radiomic feature efficacy was evaluated via receiver operating characteristic curves, and both univariate and multivariate logistic regression were used to develop predictive models. A significance level of p 
ISSN:0953-8194
1365-2826
1365-2826
DOI:10.1111/jne.13472